 |
| |
|
| |
_______________________________________
FEATURE STORY
Genome-wide association study reveals new genetic risk factor for
prostate cancer
|
| |
 The post-genomic era
has sparked a new trend in biomedical research that was scarcely
imaginable a
few years ago. Case in point: the NCI Cancer Genetic Markers of
Susceptibility (CGEMS) project, a genome-wide association study that
leverages
knowledge from the Human Genome and HapMap projects, while capitalizing
on the latest generation of DNA chip technologies. more> |
| |
_______________________________________
SPOTLIGHT
Harvard School of Public Health: The wide-angle lens of population
research
|
| |
Like a photographer
who uses a wide-angle lens to capture a sweeping landscape, the Harvard
School
of Public Health applies biological, quantitative, and social sciences
to analyze health problems across entire populations. This broad
perspective
provides a depth of insight into disease prevention -- the school's
hallmark endeavor -- while complementing basic and clinical research. more>
|
| |
______________________________________
MORE ON
CORES
Speaking of numbers
|
| |
 How many patients do you need for your clinical protocol? Which are the right questions to ask in
your lab experiments? The Biostatistics Core offers expert advice to DF/HCC members on the planning, design, and analysis of laboratory,
clinical,
and epidemiology studies, as well as consultation on grant submissions and interpretation of
study results. See Biostatistics Core Assignments for a
list of statisticians by subject area, and contact the relevant statistician at least:
- one month before a meeting abstract is due
- one month before an R01 grant is to be uploaded
- six months before a P01 or SPORE is due
|
| |
Facilitating new cell-based therapies for patients |
| |
The Cell Manipulation Core,
which houses a class 10,000 clean room, produces clinical-grade
therapeutic cells under good manufacturing practice conditions. In
addition to processing cells, the core assists DF/HCC investigators in
submitting Investigational New Drug (IND) applications by helping to
develop selection, transfection, and expansion procedures that meet FDA
manufacturing regulations. We currently support a large variety of
clinical trials in stem cell transplantation and cancer immunotherapy.
How can we
facilitate your clinical research studies? For more information,
contact Grace
Kao.
|
| |
Of mice and models |
| |
Lab investigators and animal modelers have a dedicated partner in the DF/HCC Rodent Histopathology
Core,
whose mission is to advance their research efforts. The core processes
animal tissue, prepares and stains slides for
histological analysis, and provides expert interpretation. An essential
service of the core is evaluating the validity of genetically
engineered
mouse models of human cancer and identifying unexpected phenotypes,
which may arise during experiments. Core Co-Director Roderick Bronson
also offers free one-on-one reviews of slides created at the Pathology
Cores. For more information, contact Li Zhang at 617-432-2409. To
create a new
account, visit the Pathology Core's log-in
page and follow these instructions (PDF).
|
| |
______________________________________
NEWS &
EVENTS
Three DF/HCC scientists win AACR awards
|
| |
DF/HCC Program Leaders Kenneth C.
Anderson, MD (DFCI)
and Daniel A.
Haber, MD, PhD (MGH), and member Kornelia Polyak, MD, PhD (DFCI), were honored recently at the 2007 annual meeting of the American Association for Cancer
Research
(AACR) for outstanding
accomplishments in the fight against cancer.
more>
|
| |
BIDMC recruits world-renowned geneticist |
| |
Pier Paolo Pandolfi,
MD, PhD, an award-winning cancer geneticist, will soon join the faculty
of Beth
Israel Deaconess Medical Center. Pandolfi, who comes from the Memorial
Sloan-Kettering Cancer Center, will hold joint appointments in the
departments
of medicine and pathology and serve as associate director of basic
research for BIDMC's Cancer Center as well as director of a new cancer
genetics
program. more>
|
| |
Request for promotion granted |
| |
The DF/HCC Executive
Council recently promoted the Tumor Imaging Metrics Core (TIMC) to full
core status, following a presentation by core Co-Director Gordon
Harris, PhD (MGH), who reviewed the core's current accomplishments and
future goals. TIMC helps DF/HCC clinical investigators evaluate
treatment response by providing consistent and reliable measurements of
tumors. Services include consultation, transfer of imaging studies from
the radiology departments of all DF/HCC hospitals to TIMC, and
structural or functional tumor measurements according to trial
protocol. For more information, visit TIMC's website.
|
| |
________________________________________
GRANT
UPDATES
RFPs for 2007 Nodal Awards due June 1
|
| |
 Sponsored by DF/HCC,
Nodal Awards support pilot projects that foster collaborations between
disease-
and discipline-based programs or address critical issues in cancer
disparities. The award amount is $75,000 per year for two years
($150,000 total
direct costs), with full indirect costs. Learn more.
2006 Nodal Awards:
- Parental
Attitudes Toward the HPV Vaccine
PI: Jennifer
Allen, DSc (DFCI)
Collaborators: Marcela
del Carmen, MD (MGH), Yi Li, PhD (DFCI), and JudyAnn
Bigby, MD
- MUC1 Oncoprotein Regulates the Androgen Receptor in Human Prostate
Cancer
PIs: Donald
Kufe, MD
(DFCI) and Glenn Bubley, MD (BIDMC)
- Cancer
Risk Factors and Vitamin D Supplementation in Blacks
PI: Gary
Bennett,
PhD
(DFCI)
Collaborators: Bettina Fisher Drake, PhD (DFCI) and Edward Giovannucci, MD, ScD (HSPH)
|
| |
One-time award funds unplanned needs
|
| |
Timely Special
Opportunity (TSO) Awards enable program leaders and core directors to
receive funding
quickly for new time-sensitive research, technology development, or
purchase of equipment that will contribute to the mission of DF/HCC.
The TSO is a
one-time award of up to $10,000 and includes full institutional
indirect costs. Learn
more.
New TSO Awards:
|
|
|
_____________
NEW FACES
New Members
Eighteen individuals from our seven member institutions have recently joined DF/HCC. Learn more about these scientists and their research interests.
New Leadership
In December, the following members assumed new leadership positions:
John Aster,
MD, PhD (BWH), deputy associate director, Membership
Edward Giovannucci, MD, ScD (HSPH), deputy associate director, Core Facilities
Charles Lee, PhD (BWH), director, Cytogenetics Core
Cynthia
Morton, PhD (BWH), institutional representative for BWH
Anat
Stemmer-
Rachamimov, MD (MGH), co-director, Specialized Histopathology Core
Vish
Viswanath, PhD (DFCI), director, Health Communications Core
|
|
